Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hexadecasaccharide dose-ranging study versus UFH + abciximab in UA/NSTEMI patients undergoing PCI
2004-001682-17Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2005
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sr-123781a in acute coronary syndrome (ACS), unstable angina and Myocardial Infarction (MI) (6 arms), sponsored by Sanofi. Primary endpoint: Primary composite efficacy endpoint. Started Jun 2005; status: completed.
02
Drugs
sr-123781a
03
Conditions
acute coronary syndrome (ACS)unstable anginaMyocardial Infarction (MI)
Beyond the preview
Go deeper on 2004-001682-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001682-17.